Insider Buying: TriSalus Life Sciences (NASDAQ:TLSI) CEO Purchases 39,682 Shares of Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary Szela bought 39,682 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were bought at an average price of $2.59 per share, with a total value of $102,776.38. Following the completion of the transaction, the chief executive officer directly owned 1,065,215 shares in the company, valued at approximately $2,758,906.85. This trade represents a 3.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

TriSalus Life Sciences Trading Up 13.1%

Shares of TriSalus Life Sciences stock traded up $0.35 during trading on Monday, hitting $3.03. 773,435 shares of the company were exchanged, compared to its average volume of 276,402. The firm has a market capitalization of $185.77 million, a P/E ratio of -2.15 and a beta of 0.56. TriSalus Life Sciences, Inc. has a 1-year low of $2.20 and a 1-year high of $7.95. The firm’s fifty day moving average price is $4.18 and its 200 day moving average price is $5.13. The company has a debt-to-equity ratio of 2.58, a current ratio of 5.78 and a quick ratio of 5.46.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. The company had revenue of $13.21 million for the quarter, compared to analyst estimates of $13.20 million. As a group, sell-side analysts expect that TriSalus Life Sciences, Inc. will post -0.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Canaccord Genuity Group decreased their price objective on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Lake Street Capital decreased their price objective on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Finally, Weiss Ratings lowered TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $7.50.

Institutional Investors Weigh In On TriSalus Life Sciences

Several institutional investors have recently bought and sold shares of TLSI. Goldman Sachs Group Inc. bought a new stake in TriSalus Life Sciences in the 1st quarter valued at approximately $187,000. Geode Capital Management LLC lifted its stake in TriSalus Life Sciences by 107.4% in the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock valued at $2,480,000 after acquiring an additional 235,627 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after acquiring an additional 7,519 shares in the last quarter. New York State Common Retirement Fund bought a new stake in TriSalus Life Sciences in the 2nd quarter valued at approximately $108,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $47,000. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.